Deutsche Bank set a €17.00 ($20.24) target price on Evotec (ETR:EVT) in a research report released on Tuesday morning. The firm currently has a buy rating on the stock.

Several other equities analysts have also commented on EVT. Berenberg Bank set a €13.00 ($15.48) price objective on shares of Evotec and gave the stock a neutral rating in a report on Thursday, August 10th. Oddo Securities set a €14.00 ($16.67) price objective on shares of Evotec and gave the stock a neutral rating in a report on Friday, August 11th. Finally, Oddo Bhf set a €20.00 ($23.81) price objective on shares of Evotec and gave the stock a buy rating in a report on Thursday, November 9th.

Evotec (ETR:EVT) opened at €11.89 ($14.15) on Tuesday. Evotec has a fifty-two week low of €6.05 ($7.20) and a fifty-two week high of €22.50 ($26.79).

COPYRIGHT VIOLATION NOTICE: “Deutsche Bank Analysts Give Evotec (EVT) a €17.00 Price Target” was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at https://theolympiareport.com/2017/12/08/deutsche-bank-analysts-give-evotec-evt-a-17-00-price-target.html.

About Evotec

Evotec AG provides drug discovery solutions to the pharmaceutical and biotechnology companies, academic institutions, and foundations and not-for-profit organizations worldwide. The company operates through two segments, EVT Execute and EVT Innovate. It offers drug discovery services, such as integrated services, target identification and validation, hit identification, compound management, chemistry, drug metabolism and pharmacokinetics, research informatics and in silico drug discovery, proteomics and metabolomics, cell and protein production, and in vivo and in vitro pharmacology services.

Receive News & Ratings for Evotec AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evotec AG and related companies with Analyst Ratings Network's FREE daily email newsletter.